A novel chalcone-based molecule, BDP inhibits MDA‑MB‑231 triple-negative breast cancer cell growth by suppressing Hsp90 function

Oh,Yong  Jin; Seo,Young  Ho

doi:10.3892/or.2017.5925

A novel chalcone-based molecule, BDP inhibits MDA‑MB‑231 triple-negative breast cancer cell growth by suppressing Hsp90 function

Authors:
- Yong Jin Oh
- Young Ho Seo
View Affiliations

Affiliations: College of Pharmacy, Keimyung University, Daegu 704-701, Republic of Korea
Published online on: August 25, 2017 https://doi.org/10.3892/or.2017.5925
Pages: 2343-2350

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Triple-negative breast cancer (TNBC) is a molecularly diverse and heterogeneous disease and the molecular heterogeneity of TNBC increases the difficulty in improving survival rates. To date, therapeutic approaches for the treatment of TNBC such as hormonal chemotherapy and trastuzumab-based therapy have been limited by the lack of target receptors such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (Her2), emphasizing the urgent need for identifying new therapeutic options. In this regard, heat shock protein 90 (Hsp90) has emerged as an attractive therapeutic target for TNBC. Hsp90 plays a central role in regulating correct folding, stability, and function of numerous oncogenic proteins. In the present study, we evaluated the in vitro effect of a small molecule Hsp90 inhibitor, (E)-3-(2-bromo-3,4,5-trimethoxyphenyl)-1-(2,4-dihydroxyphenyl)prop-2-en-1-one (BDP) on TNBC cell line, MDA‑MB‑231. This study indicated that BDP efficiently inhibited the growth of MDA‑MB‑231 cells in a dose- and time-dependent manner. BDP induced overall degradation of multiple oncogenic proteins including EGFR, Her2, Met, Akt, c‑Raf, and Cdk4, consequently leading to apoptotic cell death. The flow cytometric analysis revealed that BDP promoted cell cycle arrest at G2/M phases. Moreover, BDP treatment attenuated the migration of MDA‑MB‑231 cells and impaired MMP9 activity, which are essential processes for tumor metastasis. Collectively, BDP represents a new class of Hsp90 inhibitor and shows therapeutic potential for TNBC treatment.

View Figures

View References

1	Anders C and Carey LA: Understanding and treating triple-negative breast cancer. Oncology (Williston Park). 22:1233–1239; discussion 1239–1240, 1243. 2008.PubMed/NCBI
2	Osborne CK and Schiff R: Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 62:233–247. 2011. View Article : Google Scholar : PubMed/NCBI
3	Baselga J: Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. Oncologist. 16 Suppl 1:12–19. 2011. View Article : Google Scholar : PubMed/NCBI
4	Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, et al: NCCN Guidelines Insights Breast Cancer, Version 1.2016. J Natl Compr Canc Netw. 13:1475–1485. 2015. View Article : Google Scholar : PubMed/NCBI
5	Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W and Toppmeyer D: Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 24:5652–5657. 2006. View Article : Google Scholar : PubMed/NCBI
6	Cheng Q, Chang JT, Geradts J, Neckers LM, Haystead T, Spector NL and Lyerly HK: Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer. Breast Cancer Res. 14:R622012. View Article : Google Scholar : PubMed/NCBI
7	Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA: Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
8	Sankhala KK, Mita MM, Mita AC and Takimoto CH: Heat shock proteins: A potential anticancer target. Curr Drug Targets. 12:2001–2008. 2011. View Article : Google Scholar : PubMed/NCBI
9	Bishop SC, Burlison JA and Blagg BS: Hsp90: A novel target for the disruption of multiple signaling cascades. Curr Cancer Drug Targets. 7:369–388. 2007. View Article : Google Scholar : PubMed/NCBI
10	Zuehlke A and Johnson JL: Hsp90 and co-chaperones twist the functions of diverse client proteins. Biopolymers. 93:211–217. 2010. View Article : Google Scholar : PubMed/NCBI
11	Mahalingam D, Swords R, Carew JS, Nawrocki ST, Bhalla K and Giles FJ: Targeting HSP90 for cancer therapy. Br J Cancer. 100:1523–1529. 2009. View Article : Google Scholar : PubMed/NCBI
12	Hanahan D and Weinberg RA: The hallmarks of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
13	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
14	Normant E, Paez G, West KA, Lim AR, Slocum KL, Tunkey C, McDougall J, Wylie AA, Robison K, Caliri K, et al: The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. Oncogene. 30:2581–2586. 2011. View Article : Google Scholar : PubMed/NCBI
15	Mishra L, Sinha R, Itokawa H, Bastow KF, Tachibana Y, Nakanishi Y, Kilgore N and Lee KH: Anti-HIV and cytotoxic activities of Ru(II)/Ru(III) polypyridyl complexes containing 2,6-(2′-benzimidazolyl)-pyridine/chalcone as co-ligand. Bioorg Med Chem. 9:1667–1671. 2001. View Article : Google Scholar : PubMed/NCBI
16	Chen M, Christensen Brøgger S, Zhai L, Rasmussen MH, Theander TG, Frøkjaer S, Steffansen B, Davidsen J and Kharazmi A: The novel oxygenated chalcone, 2,4-dimethoxy-4′-butoxychalcone, exhibits potent activity against human malaria parasite Plasmodium falciparum in vitro and rodent parasites Plasmodium berghei and Plasmodium yoelii in vivo. J Infect Dis. 176:1327–1333. 1997. View Article : Google Scholar : PubMed/NCBI
17	Ducki S: The development of chalcones as promising anticancer agents. IDrugs. 10:42–46. 2007.PubMed/NCBI
18	Chua AW, Hay HS, Rajendran P, Shanmugam MK, Li F, Bist P, Koay ES, Lim LH, Kumar AP and Sethi G: Butein downregulates chemokine receptor CXCR4 expression and function through suppression of NF-κB activation in breast and pancreatic tumor cells. Biochem Pharmacol. 80:1553–1562. 2010. View Article : Google Scholar : PubMed/NCBI
19	Katsori AM and Hadjipavlou-Litina D: Chalcones in cancer: Understanding their role in terms of QSAR. Curr Med Chem. 16:1062–1081. 2009. View Article : Google Scholar : PubMed/NCBI
20	Liu X and Go ML: Antiproliferative properties of piperidinylchalcones. Bioorg Med Chem. 14:153–163. 2006. View Article : Google Scholar : PubMed/NCBI
21	Modzelewska A, Pettit C, Achanta G, Davidson NE, Huang P and Khan SR: Anticancer activities of novel chalcone and bis-chalcone derivatives. Bioorg Med Chem. 14:3491–3495. 2006. View Article : Google Scholar : PubMed/NCBI
22	Jeong JH, Oh YJ, Kwon TK and Seo YH: Chalcone-templated Hsp90 inhibitors and their effects on gefitinib resistance in non-small cell lung cancer (NSCLC). Arch Pharm Res. 40:96–105. 2017. View Article : Google Scholar : PubMed/NCBI
23	Jeong JH, Oh YJ, Lho Y, Park SY, Liu KH, Ha E and Seo YH: Targeting the entry region of Hsp90's ATP binding pocket with a novel 6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl amide. Eur J Med Chem. 124:1069–1080. 2016. View Article : Google Scholar : PubMed/NCBI
24	Jeong CH, Park HB, Jang WJ, Jung SH and Seo YH: Discovery of hybrid Hsp90 inhibitors and their anti-neoplastic effects against gefitinib-resistant non-small cell lung cancer (NSCLC). Bioorg Med Chem Lett. 24:224–227. 2014. View Article : Google Scholar : PubMed/NCBI
25	Lee T and Seo YH: Targeting the hydrophobic region of Hsp90's ATP binding pocket with novel 1,3,5-triazines. Bioorg Med Chem Lett. 23:6427–6431. 2013. View Article : Google Scholar : PubMed/NCBI
26	Seo YH and Jeong JH: Synthesis of butein analogues and their anti-proliferative activity against gefitinib-resistant non-small cell lung cancer (NSCLC) through Hsp90 inhibition. Bull Korean Chem Soc. 35:1294–1298. 2014. View Article : Google Scholar
27	Chacón RD and Costanzo MV: Triple-negative breast cancer. Breast Cancer Res. 12 Suppl 2:S32010. View Article : Google Scholar
28	Elias AD: Triple-negative breast cancer: A short review. Am J Clin Oncol. 33:637–645. 2010. View Article : Google Scholar : PubMed/NCBI
29	Hudis CA and Gianni L: Triple-negative breast cancer: An unmet medical need. Oncologist. 16 Suppl 1:1–11. 2011. View Article : Google Scholar : PubMed/NCBI
30	Andreopoulou E, Schweber SJ, Sparano JA and McDaid HM: Therapies for triple negative breast cancer. Expert Opin Pharmacother. 16:983–998. 2015. View Article : Google Scholar : PubMed/NCBI
31	Sidera K and Patsavoudi E: Extracellular HSP90: Conquering the cell surface. Cell Cycle. 7:1564–1568. 2008. View Article : Google Scholar : PubMed/NCBI
32	Sekihara K, Harashima N, Tongu M, Tamaki Y, Uchida N, Inomata T and Harada M: Pifithrin-μ, an inhibitor of heat-shock protein 70, can increase the antitumor effects of hyperthermia against human prostate cancer cells. PLoS One. 8:e787722013. View Article : Google Scholar : PubMed/NCBI
33	Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y, Simmons L, Maloney A, Raynaud F, Campbell M, et al: Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol. 23:4152–4161. 2005. View Article : Google Scholar : PubMed/NCBI
34	Viktorsson K, Lewensohn R and Zhivotovsky B: Apoptotic pathways and therapy resistance in human malignancies. Adv Cancer Res. 94:143–196. 2005. View Article : Google Scholar : PubMed/NCBI
35	Jiang X and Wang X: Cytochrome C-mediated apoptosis. Annu Rev Biochem. 73:87–106. 2004. View Article : Google Scholar : PubMed/NCBI
36	Tseng LM, Hsu NC, Chen SC, Lu YS, Lin CH, Chang DY, Li H, Lin YC, Chang HK, Chao TC, et al: Distant metastasis in triple-negative breast cancer. Neoplasma. 60:290–294. 2013. View Article : Google Scholar : PubMed/NCBI
37	Trinca F, Inacio M, Timoteo T and Dinis R: Triple-negative breast cancer with brain metastasis in a pregnant woman. BMJ Case Rep 20172017. doi:10.1136/bcr-2016-218657.